title: Antithrombotic therapy: triple therapy or triple threat?
abstract: Antithrombotic therapy plays an essential role in the management of some of the most common and morbid medical conditions. Triple oral antithrombotic therapy (TOAT) is defined as the administration of both therapeutic oral anticoagulation (OAC) and dual antiplatelet therapy (DAPT) to patients with indications for both treatments. The current societal guidelines regarding TOAT are derived from observational studies and some trials of the use of warfarin in addition to antiplatelet therapy in patients with atrial fibrillation and a recent acute coronary syndrome or percutaneous coronary intervention. The general apprehension to administer TOAT is due to the heightened concern for bleeding, rendering warfarin's pharmacokinetic properties concerning. Newer anticoagulant agents may serve as appealing alternatives, and further investigations are warranted. The results of the recent trials that have studied the use of these agents in atrial fibrillation and acute coronary syndrome offer some useful applications to TOAT. Ultimately, selecting the most favorable antithrombotic strategy is going to involve weighing the risks and benefits for each patient.
authors.affiliation: Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. jmega@partners.org
authors.forename: Jessica
authors.initials: J
authors.lastname: Mega
authors.forename: Edward T
authors.initials: ET
authors.lastname: Carreras
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy; D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006405:Hematology / Q000379:methods*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D012306:Risk; D020521:Stroke / Q000517:prevention & control; D013923:Thromboembolism / Q000517:prevention & control / Q000628:therapy; D013927:Thrombosis / Q000517:prevention & control / Q000628:therapy; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin